India Struggles with High Hepatitis Mortality: WHO Report

India’s Struggle with Viral Hepatitis

India continues to face a significant public health challenge as the India hepatitis burden remains among the highest globally. According to the WHO’s Global Hepatitis Report 2026, the world is currently off track to meet the 2030 elimination targets. Specifically, viral hepatitis claimed over 1.3 million lives globally in 2024. Most of these deaths resulted from hepatitis B and C infections which affect liver health silently. Furthermore, India is one of the ten countries accounting for nearly 69% of global hepatitis B deaths. It also accounts for 58% of global hepatitis C deaths. Consequently, the nation ranks second only to Pakistan in terms of the total hepatitis C burden.

The Challenges of India Hepatitis Burden

Health experts note that the primary issue is not treatment access but rather under-diagnosis. For instance, Dr. Piyush Ranjan from Sir Gangaram Hospital emphasizes that gaps in vaccination coverage and unsafe medical exposures remain prevalent. Additionally, missed opportunities for screening during pregnancy contribute significantly to the problem. Because hepatitis B often spreads from mother to child in early childhood, routine screening is vital. Currently, India falls in the intermediate hepatitis B burden category. This status translates to approximately 40 million people living with chronic infections. Although free treatment for hepatitis C has expanded, awareness and long-term compliance remain weak. Therefore, achieving the 2030 elimination goal appears unlikely at the current pace.

Strategies for Improving Clinical Outcomes

Globally, new hepatitis B infections have decreased by 32% since 2015. However, hepatitis B deaths have risen by 17% due to diagnosis gaps. In contrast, hepatitis C deaths have fallen by 12%. Despite these shifts, only a small fraction of eligible patients receive therapy. Specifically, fewer than 5% of hepatitis B patients are on treatment globally. To reverse this trend, the WHO calls for scaling up vaccination and safer medical practices. Medical professionals must prioritize screening and long-term treatment compliance to reduce the India hepatitis burden effectively. Enhanced awareness among healthcare providers, often gained through specialized gastroenterology training, can bridge the gap in diagnosis and help reach global targets.

Frequently Asked Questions

Q1: What is the main cause of the high hepatitis burden in India?

The high burden stems from under-diagnosis, gaps in vaccination coverage, and unsafe exposures such as needle sharing. Additionally, mother-to-child transmission remains a significant factor in chronic cases. For those managing such complex cases, pursuing a certification course in general practice can provide essential updates on screening and public health protocols.

Q2: Is India on track to eliminate hepatitis by 2030?

According to current estimates and the WHO 2026 report, India is currently off track to meet the 2030 elimination targets. This delay is due to slow progress in screening and low treatment compliance.

Q3: Which types of hepatitis contribute most to mortality in India?

Hepatitis B and C together account for more than 95% of all hepatitis-related deaths globally and in India, often leading to cirrhosis and liver cancer. Clinicians looking to specialize in managing such liver-related conditions can explore postgraduate diploma in gastroenterology to enhance their clinical expertise.

References

1. India among worst-hit as hepatitis deaths stay high despite global gains: WHOreport – ETHealthworld
2. World Health Organization. Global Hepatitis Report 2024: Action for access in low- and middle-income countries.
3. Indian Council of Medical Research (ICMR). Prevalence and Disease Burden of Viral Hepatitis in India.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.